Cross-border medtech and biotech US commercialisation.
The full pillar on non-US medtech and biotech firms entering US health-system, US KOL, and US payer commercialisation across corridors.
Read the pillar →
Published 3 May 2026 · Global Marketing Agency
The pattern repeats across German medtech firms at the point they decide to commercialise in the United States. The principal is the chief executive, the chief medical officer, the chief regulatory officer, or the family-shareholder representative inside a Mittelstand medtech house. The firm carries decades of European clinical reference, MDR conformity files in deep technical depth, and Notified Body relationships with TÜV SÜD, TÜV Rheinland, DEKRA, BSI, or DQS. The home-market position is established. The US commercialisation question arrives as a board agenda item, a private-equity sponsor mandate, or a strategic-investor instruction following a US-side Series B or growth round.
The archetype concentrates in identifiable corridors. Erlangen, Munich, and the wider Bavarian medtech cluster carry Siemens Healthineers, BrainLab, and a long tail of imaging, surgical-robotics, and clinical-decision-support operators. Tuttlingen carries Karl Storz, Aesculap (B. Braun), and the surgical-instrument cluster that supplies a meaningful share of the global rigid-endoscope market. Duderstadt carries Otto Bock and the orthopaedic-prosthetics cluster. Lübeck carries Drägerwerk in respiratory and anaesthesia. Melsungen carries B. Braun in infusion, dialysis, and pharmaceutical containment. Bad Homburg carries Fresenius Medical Care. Heidenheim carries Hartmann in wound care and infection prevention. Göttingen carries Sartorius in bioprocessing and laboratory diagnostics. Hamburg carries Eppendorf in life-science instrumentation. Each is a distinct sub-vertical inside the broader German medtech architecture, and each has a different FDA pathway profile.
The shared pattern across these firms is that the US commercial conversation begins after MDR conformity is in place, often after a Notified Body audit cycle has just been completed and the technical documentation file is structurally complete in MDR terms. The principal reads the FDA pathway as a translation exercise on top of an already-complete European file. The translation is partial. Significant components of the FDA submission, including US-acceptable clinical evidence, US predicate-device analysis, US labelling, US human factors and usability validation under IEC 62366-1 with FDA-specific overlays, US software validation under FDA software guidance for software-as-a-medical-device, and the US Quality System Regulation under 21 CFR Part 820, are separately constructed objects.
The principal's question is typically: how long does the FDA submission take, what does it cost, and when can we begin US selling. The frame the firm contributes is not the regulatory timeline (that belongs with FDA-specialist counsel) but the US commercial frame the firm will need on the day FDA clearance lands. The same eighteen-to-thirty-six month parallel-build window applies to German medtech as to other non-US medtech corridors, and the German operator who treats the FDA pathway as the only US-bound work loses the eighteen-to-thirty-six months that the US KOL, US payer, US Medicare coding, US specialty-society visibility, and US health-system procurement architecture need.
The Medical Device Regulation EU 2017/745 (MDR) governs medical-device conformity in the European Union. It came into full application in May 2021 for new devices and entered transitional periods for legacy devices that vary by class and by Notified Body capacity. The MDR replaced the earlier Medical Device Directive (MDD 93/42/EEC) and significantly raised the documentation, post-market surveillance, and clinical-evidence expectations. A German medtech firm that completed a fresh MDR conformity cycle is operating with a substantially deeper technical-documentation file than the same firm held under MDD.
The MDR classification framework runs Class I (lowest risk), Class IIa, Class IIb, Class III (highest risk), and Class IIb implantable. The conformity-assessment route depends on class, and Class IIa and above require Notified Body involvement. The technical documentation under Annex II covers device description, design and manufacturing information, general safety and performance requirements, benefit-risk analysis, risk management, product verification and validation, and post-market surveillance.
The FDA framework runs through 21 CFR Parts 800-1299, with the device-specific provisions concentrated in Parts 800-898. The classification is Class I, Class II, and Class III, with regulatory pathway driven by a combination of class and predicate-device analysis. Class I devices are typically subject to general controls only and many are 510(k)-exempt. Class II devices typically require a 510(k) substantial-equivalence submission to a legally-marketed predicate. Class III devices typically require a Premarket Approval (PMA) submission under 21 CFR Part 814 and a separate Investigational Device Exemption (IDE) under 21 CFR Part 812 to conduct US clinical investigation. De Novo classification under 21 CFR Part 860 Subpart D applies to novel low-to-moderate-risk devices that have no predicate.
The translation gap is structural. An MDR Class IIb device is not automatically an FDA Class II device. An MDR Class III device is not automatically an FDA Class III device. The FDA classification is driven by US predicate analysis and US risk reasoning, not by EU classification. An MDR Annex II clinical-evaluation report is not an FDA-acceptable clinical-evidence package. The US clinical evidence may need to be regenerated at US sites, with US patient populations, under US Good Clinical Practice and IRB oversight, and with US-specific endpoints. ISO 14971 risk-management documentation translates substantially into FDA risk-analysis expectations but the FDA reviewer reads against US-specific guidance documents that vary by device category.
The marketing implication is that the German medtech firm cannot lead a US commercial conversation with CE-mark and Notified Body credentials as the validating proof. The US health-system procurement officer, US KOL, US payer, and US specialty society read CE-mark as European context and not as US clinical or regulatory authority. The US-bound proof has to be regenerated. The firm contributes the US commercial frame around that regeneration.
The four FDA marketing pathways relevant to German medtech are 510(k), De Novo, PMA, and the IDE that supports investigational use ahead of a marketing submission. Each carries distinct evidence, timeline, and US commercial-frame implications.
510(k) substantial equivalence. The 510(k) under 21 CFR Part 807 Subpart E requires the sponsor to demonstrate that the new device is substantially equivalent to a legally-marketed predicate. Substantial equivalence rests on intended use and technological characteristics, with performance data demonstrating that any technological differences do not raise new questions of safety and effectiveness. German medtech firms typically use 510(k) for surgical instruments, imaging accessories, diagnostic devices, infusion components, anaesthesia accessories, and orthopaedic devices where established US predicates exist. The submission is reviewed under the FDA's Medical Device User Fee Amendments (MDUFA) timelines, with target review in the order of low-to-mid hundreds of days for traditional 510(k) and faster for Special and Abbreviated 510(k). The clinical-evidence requirement varies by device category.
De Novo classification. The De Novo pathway under 21 CFR Part 860 Subpart D applies to novel devices of low-to-moderate risk that have no predicate. The sponsor petitions the FDA to classify the device into Class I or Class II, generating a new classification regulation and special controls. German medtech firms typically use De Novo for AI-enabled diagnostic software, novel surgical-robotics applications, novel digital-health categories, and clinical-decision-support tools where no clear US predicate exists. The De Novo timeline is typically longer than 510(k) and shorter than PMA, and the granted device becomes a future predicate for subsequent 510(k) submissions.
Premarket Approval (PMA). PMA under 21 CFR Part 814 is the FDA pathway for Class III devices, which the FDA reserves for devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. The PMA is the most evidence-intensive pathway and typically requires an IDE-supported pivotal US clinical investigation. German medtech firms typically encounter PMA in cardiovascular implants, neurological stimulators, certain diagnostic categories, and surgical-robotics applications. PMA approval is supplemented by post-approval study commitments, MDR (FDA Medical Device Reporting under 21 CFR Part 803) post-market obligations, and Quality System Inspection (QSI) cadence.
Investigational Device Exemption (IDE). The IDE under 21 CFR Part 812 authorises shipment of an investigational device for clinical investigation to support a 510(k), De Novo, or PMA submission. Significant-risk and non-significant-risk distinctions drive the FDA review depth. The German medtech firm using IDE for US clinical evidence faces site selection, IRB approval, US Good Clinical Practice oversight, US-side clinical operations, and US-side principal-investigator engagement. The IDE-pivotal trial is often where the US KOL architecture is built in parallel: the named US principal investigators, the named US sites, the named US specialty-society visibility, and the named US clinical-evidence base are constructed during the IDE phase, not after PMA approval.
ISO 13485 is the international quality-management-system standard for medical devices and is the basis for MDR conformity in Europe. FDA Quality System Regulation under 21 CFR Part 820 is the US analogue. The two standards substantially overlap but are not identical, and the gap matters for German medtech firms entering FDA jurisdiction.
FDA published a final rule in early 2024 to harmonise the QSR with ISO 13485:2016, with a transition period ending in early 2026. The harmonised regulation, designated the Quality Management System Regulation (QMSR), replaces 21 CFR Part 820 with provisions that incorporate ISO 13485 by reference. The transition reduces the structural gap between ISO 13485 and US-specific QSR requirements but does not eliminate it. The QMSR retains FDA-specific provisions on labelling, complaint handling, MDR (Medical Device Reporting under 21 CFR Part 803), and post-market surveillance that are not coextensive with ISO 13485.
For the German medtech firm, the operational consequence is that ISO 13485 certification by a Notified Body is necessary but not sufficient for FDA establishment registration and listing under 21 CFR Part 807. The firm must register as a manufacturer of devices for US commercial distribution, list each device, and submit to FDA Quality System Inspection on a risk-based cadence. The firm must designate a US Agent under 21 CFR Part 807.40 if the manufacturer is foreign. The US Agent is a US-resident or US-business contact for FDA communication and is a necessary regulatory infrastructure object that the German firm has to put in place, typically through a US-resident regulatory consultant or a US subsidiary.
The FDA Quality System Inspection itself, conducted by the FDA Office of Regulatory Affairs investigators, follows the Quality System Inspection Technique (QSIT) and produces 483 observations on inspectional findings and Establishment Inspection Reports. The German firm whose first FDA inspection produces a Form 483 with multiple observations has a regulatory-response obligation that can compress US commercial activity for months. The marketing implication is that the FDA QSI readiness is part of the broader US-readiness picture, and the firm's US KOL, US payer, and US procurement readers indirectly read FDA-inspection track record through the firm's commercial signal.
The FDA Q-Submission programme is the formal channel for sponsor-FDA interaction before a marketing or investigational submission. The programme is administered through the Center for Devices and Radiological Health (CDRH) for devices, with parallel programmes at the Center for Biologics Evaluation and Research (CBER) for biologic-device combinations and the Center for Drug Evaluation and Research (CDER) for drug-device combinations.
The Q-Submission categories include the Pre-Submission, the Submission Issue Request, the Study Risk Determination, the Informational Meeting, the Agreement Meeting, the Determination Meeting, and the Breakthrough Device Designation request. The Pre-Submission is the most common entry point and typically generates a written FDA response and an FDA meeting if requested. The Submission Issue Request addresses specific issues during an active review. The Study Risk Determination determines whether a planned clinical investigation is significant-risk or non-significant-risk for IDE purposes.
For the German medtech firm, the Q-Submission programme is the structured way to surface FDA-pathway uncertainty before formal submission. A Pre-Sub on classification, a Pre-Sub on predicate-adequacy for a 510(k), a Pre-Sub on De Novo eligibility, a Pre-Sub on the proposed pivotal-trial design supporting a PMA, or a Pre-Sub on AI-enabled software classification are all standard uses. The Pre-Sub is not a substitute for the formal submission but it materially de-risks the submission timeline.
The Q-Submission package itself is constructed to FDA expectations under the relevant Q-Sub guidance and includes a clearly-stated regulatory question, the proposed device description, the proposed regulatory pathway, the proposed clinical and non-clinical evidence, and specific questions for FDA response. The work is conducted by FDA-specialist regulatory counsel and consultancies. The firm contributes the US commercial frame that runs in parallel with the Q-Sub timeline and that the firm will need on the day a positive Q-Sub feedback is obtained.
The Breakthrough Devices Programme was established by the 21st Century Cures Act and codified through the FDA Reauthorization Act of 2017 (FDARA) Section 3051, with statutory authority at 21 USC 360e-3. Designation provides priority FDA review, intensified sponsor-FDA communication, and senior FDA management engagement. Designation does not lower evidentiary standards but does compress timelines and increase FDA responsiveness.
Eligibility requires that the device provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions and meet at least one of four secondary criteria: representing breakthrough technology, having no approved or cleared alternatives, offering significant advantages over existing approved or cleared alternatives, or being in the best interest of patients on availability grounds. The designation request is submitted through the Q-Submission channel and reviewed by CDRH against the statutory criteria.
German medtech categories that have historically secured Breakthrough Device Designation include surgical robotics in oncology and complex orthopaedic indications, cardiovascular structural-heart devices, neurological stimulators in refractory indications, AI-enabled diagnostic software for cancer detection, oncology imaging contrast agents, and rare-disease device categories. The FDA has granted hundreds of Breakthrough designations across the programme's life and granted clearance or approval to a meaningful subset, with timelines compressed relative to non-Breakthrough comparators.
The marketing implication for the German medtech firm holding Breakthrough Device Designation is twofold. The designation is a credible US-readable signal of FDA-recognised novelty and clinical importance, and it is appropriate to surface in US-facing materials. The designation is not a substitute for the US KOL, US payer, US specialty-society, US Medicare coding, and US health-system procurement architecture, and the firm that treats Breakthrough designation as the US commercial proof point loses the parallel-build window that the US KOL panel and US payer architecture need. The Breakthrough device that arrives at FDA clearance with no US KOL panel, no US payer value dossier, and no US specialty-society visibility lands into the same eighteen-to-thirty-six month commercial gap as a non-Breakthrough device.
The clinical-evidence translation from MDR to FDA is the single most consequential surface where German medtech firms underestimate the gap. Under MDR, the clinical evaluation is constructed under MDR Article 61 and Annex XIV, with a Clinical Evaluation Plan, clinical investigations under Annex XV where required, the clinical evaluation report, and post-market clinical follow-up. The clinical-evidence base typically draws on European clinical sites, European patient populations, European clinical investigators, and European good clinical practice oversight under ISO 14155.
The FDA reads clinical evidence with US-specific expectations. US Good Clinical Practice oversight, US IRB approval at US sites, US-population enrolment for representativeness, US-specific endpoints calibrated to FDA guidance for the device category, and US-investigator engagement are central. The FDA does accept foreign clinical data under 21 CFR Part 814.15 for PMA and analogous provisions for IDE, but acceptance is conditional on the data being applicable to the US population, the foreign clinical investigations being conducted in accordance with Good Clinical Practice, and the FDA being able to validate the data through on-site inspection where requested.
For most German medtech firms entering FDA jurisdiction with MDR-vintage European clinical evidence, the FDA will require some US clinical evidence regardless of foreign-data acceptance. The proportion varies by device class and category. A 510(k) with a strong predicate may proceed on European clinical evidence supplemented by US human-factors validation. A De Novo for an AI-enabled diagnostic typically requires a US-population validation cohort. A PMA for a Class III implant typically requires a US pivotal trial under IDE.
The US-side clinical investigation is not only a regulatory event. It is the architecture inside which the US KOL panel is built. The named US principal investigators, the named US clinical sites, the named US site-management teams, and the named US specialty-society relationships are the same names the firm will need at FDA clearance day for US commercial launch. A German medtech firm that engages with US-side clinical investigation as a regulatory cost rather than as a US commercial-foundation event misses the parallel-build opportunity that the IDE-pivotal trial structurally provides.
US key-opinion-leader architecture is the first US commercial layer that German medtech firms typically defer until after FDA clearance. The deferral is structural: the German firm reads US KOL engagement as a launch-marketing activity that follows clearance rather than as a US commercial foundation that runs parallel to the FDA pathway.
The US KOL landscape in any device category is composed of named US clinicians at named US academic medical centres and named US integrated delivery networks, named US specialty societies and the committee structures within them, and named US patient-advocacy networks where category-relevant. For surgical robotics, the US KOL landscape includes named surgical clinicians at academic surgical centres and the relevant US surgical societies. For cardiovascular implants, the US KOL landscape includes interventional cardiologists at structural-heart programmes and the American College of Cardiology and Society for Cardiovascular Angiography and Interventions communities. For oncology imaging, the US KOL landscape includes radiation oncologists, medical oncologists, and radiologists at named US comprehensive cancer centres and the American Society of Clinical Oncology and Radiological Society of North America communities.
The German medtech firm's parallel-build US KOL work begins with identification (which US clinicians and which US institutions are category-defining), proceeds through engagement (advisory-panel structure, US-site clinical-evidence collaboration, US specialty-society sponsorship, US conference visibility), and matures into a US KOL panel that produces US clinical-evidence publications, US specialty-society category-language validation, and US KOL endorsement for US health-system procurement readers and US payer formulary committees. The window for this work is the eighteen-to-thirty-six months that the FDA pathway is running. The work cannot be compressed into the weeks before launch.
US payer architecture is the second US commercial layer and the one most often left until after clearance with the steepest cost. The US payer landscape includes US commercial payers (United, Anthem-Elevance, Cigna, Aetna-CVS, BCBS plans, Humana, and the named regional payers), US Medicare (Centers for Medicare & Medicaid Services, Medicare Administrative Contractors, and the Local Coverage Determination and National Coverage Determination processes), US Medicaid (with state-level variation), and US VA and Department of Defense health systems.
US Medicare coding is the gating layer for US commercial-payer adoption in many medtech categories. The relevant coding pathways are CPT (Current Procedural Terminology, AMA-administered) for procedures, HCPCS (Healthcare Common Procedure Coding System) Level II for products and services not covered by CPT, ICD-10-CM and ICD-10-PCS for diagnosis and inpatient procedure coding, APC (Ambulatory Payment Classification) for outpatient hospital payment, and MS-DRG (Medicare Severity Diagnosis-Related Group) for inpatient hospital payment. New CPT codes follow an annual AMA CPT Editorial Panel cycle and typically take two-to-three years from application to active code. New HCPCS Level II codes follow a quarterly CMS cycle. New technology add-on payment under MS-DRG follows annual CMS rulemaking with structured criteria including newness, cost, and substantial clinical improvement.
The German medtech firm that begins US Medicare coding work on FDA clearance day is at clearance day with US Medicare coding eighteen-to-twenty-four months out. The named US commercial payers will not move ahead of US Medicare in many categories. The US value dossier, written to the AMCP Format for Formulary Submissions and US-payer-acceptable health-economics evidence standards, is a parallel object that the firm constructs alongside the FDA pathway. The US health-economics positioning under value-based-care frames, alternative-payment-model frames, and budget-impact-model frames is calibrated to the US payer reader rather than the European HTA reader. The work belongs partly with US health-economics-and-outcomes-research counterparties and partly with the firm's commercial buildout. The firm contributes the US-facing positioning, naming, and reader-calibration work.
The FDA Quality System Inspection (QSI), conducted by FDA Office of Regulatory Affairs investigators under the Quality System Inspection Technique (QSIT), is a periodic on-site audit of the manufacturer's quality system. For German medtech firms, the inspection occurs at the German manufacturing facility (or the relevant US facility if the firm has manufactured in the US), with FDA investigators travelling to the site. Inspections are scheduled on a risk-based cadence, with high-risk Class III device manufacturers typically subject to biennial inspection and lower-risk manufacturers on longer cycles.
Inspection outcomes include a Form 483 (Inspectional Observations) where the investigator identifies deviations from the QSR, an Establishment Inspection Report, and potentially a Warning Letter where the FDA escalates regulatory concern. The firm's response to a 483 is a structured corrective-and-preventive-action process that the FDA reviews. A Warning Letter is a public document published on the FDA website and is a US-readable signal that named US health-system procurement officers, US KOLs, and US payers will encounter through standard due-diligence searches.
The marketing implication is that FDA QSI readiness, 483 response track record, and Warning Letter posture are part of the broader US commercial-readiness picture. A German medtech firm with strong MDR conformity but a recent FDA Warning Letter has a US commercial obstacle that no amount of MDR proof will offset. The fix is FDA-specialist regulatory remediation work, which belongs with FDA-specialist counsel and consultancies. The firm's contribution is to surface the firm's US readiness in US-legible terms once the regulatory posture is stable, and to design the US commercial frame so that QSI cadence and post-market surveillance are integrated into the US health-system procurement reader's reading.
German medtech firms with full MDR conformity typically discover the FDA submission is not a translation of the European file but a distinct US-side construction. The eighteen-to-thirty-six month parallel-build window for US KOL, US payer, US Medicare coding, and US specialty-society architecture is the same window the FDA pathway runs in. The firm that uses that window builds a category position. The firm that runs the FDA pathway alone arrives at clearance day with the commercial frame still ahead. House view on the MDR-to-FDA bridge
Three stages in order. The order matters. Building US commercial materials on a serial-build assumption produces cleaner execution on the same misread.
Diagnose. The first stage identifies where the US commercial frame is breaking against the FDA pathway. The diagnosis surfaces which US commercial layers (US KOL, US payer, US Medicare coding, US clinical-society visibility, US health-system procurement) are missing or thin, where the MDR-to-FDA translation is being treated as automatic rather than as a substantive regeneration, and which US readers are encountering home-market and CE-mark language they do not complete. The diagnosis is firm-specific. A Munich surgical-robotics firm at IDE-pivotal stage has a different first break than a Tuttlingen surgical-instruments firm at 510(k) substantial-equivalence stage or a Lübeck respiratory-device firm at PMA module submission.
Correct the signal. The second stage rebuilds the US-facing commercial frame in parallel with the FDA pathway. The US clinical category is named at the front in US-legible terms. The US KOL panel is built at category-relevant US academic medical centres. The US value dossier is drafted to AMCP Format for Formulary Submissions and US-commercial-payer evidence standards. The US Medicare coding-pathway groundwork is started for CPT, HCPCS, ICD-10, APC, and MS-DRG work as relevant. The US health-economics positioning is calibrated to the US payer reader. The US health-system procurement readiness is staged at named US integrated delivery networks. CE-mark and MDR conformity continue to carry European audiences. The US-facing surface is rebuilt in parallel.
Rebuild the execution layer in parallel with the FDA pathway. The third stage rebuilds the surfaces the US health-system procurement officer, US KOL, US payer, and US specialty-society reader encounter. US-facing principal and clinical-team bios with US-based commercial leadership surfaced, US KOL relationships and advisory-panel structure, US-facing site and sales architecture, US clinical-society and US conference plan, US payer-facing materials and value dossier, US health-system procurement-facing materials, US-facing legal and contractual templates, and the US commercial cadence the US health-system reader expects. The execution layer sits on top of the corrected frame. Done in parallel with the FDA pathway, it produces a US commercial frame that is launch-ready on FDA clearance day. Done after clearance, it produces an eighteen-to-thirty-six month gap in which the US-headquartered competitor or the parallel-build competitor takes the category.
The firm runs three engagements for German medtech operators. Fit and pricing are confirmed in discovery, not published.
For corridor-level reading, see the Munich city page, the Munich operators page, the cross-border medtech and biotech pillar, the Germany to USA 2026 entry guide, and the DACH Mittelstand industrials and engineering entry pillar.
No. CE-mark conformity under the EU Medical Device Regulation 2017/745 is a separate regulatory event from FDA clearance and the two regimes do not cross-recognise. A German medtech operator with a Class IIa or Class IIb CE-mark and a complete MDR Annex II technical documentation file still has the full FDA submission ahead, whether 510(k) substantial-equivalence, De Novo classification, IDE under 21 CFR Part 812, or PMA under 21 CFR Part 814. ISO 13485 quality-system certification is closer to but not identical with the FDA Quality System Regulation under 21 CFR Part 820. The regulatory translation is real and substantive, and the marketing claim that a CE-mark device is automatically FDA-eligible is incorrect. Defer all FDA submission, IDE, 510(k), De Novo, and PMA work to FDA-specialist regulatory counsel and consultancies. The firm contributes the US commercial frame around that work.
The FDA Q-Submission programme is the formal channel through which a sponsor obtains FDA written feedback before a marketing or investigational submission. Q-Sub categories include the Pre-Submission, the Submission Issue Request, the Study Risk Determination, and the Informational Meeting. A German medtech operator that has a Class III device under MDR but is unclear whether the FDA pathway is De Novo or PMA, that holds clinical evidence generated in EU sites and wants FDA feedback on US-acceptability, that is unsure whether a 510(k) predicate exists at adequate similarity, or that has a novel software-as-a-medical-device or AI-enabled device classification question, is the typical Q-Sub user. The Pre-Sub meeting is scheduled with the relevant FDA review division (CDRH for devices, CBER for biologic-device combination, CDER for drug-device combination). The substantive Q-Sub work belongs with FDA-specialist regulatory counsel.
Breakthrough Device Designation under FDARA Section 3051 (codified at 21 USC 360e-3) provides priority FDA review and intensified sponsor-FDA communication for devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions and that meet at least one of four criteria including representing breakthrough technology, having no approved alternative, offering significant advantage over existing approved alternatives, or otherwise being in the best interest of patients. German medtech categories that have historically used the designation include surgical robotics, cardiovascular implants, neurological stimulators, oncology imaging, AI-enabled diagnostic software, and rare-disease device categories. Designation is requested through the Q-Submission channel. The marketing implication is that a Breakthrough-designated device receives faster FDA review but the US KOL, US payer, US specialty-society, and US health-system procurement architecture still need eighteen-to-thirty-six months of parallel build.
No. FDA submissions including 510(k), De Novo, IDE under 21 CFR Part 812, PMA under 21 CFR Part 814, Q-Submissions, Breakthrough Device Designation requests, biologic INDs, BLAs, post-market surveillance, FDA Quality System Inspection (QSI) response, FDA 483 observation response, and FDA enforcement actions belong with FDA-specialist regulatory counsel and consultancies. MDR EU 2017/745 conformity, Notified Body interaction, ISO 13485 audit, and CE-mark technical documentation belong with EU regulatory specialists. The firm designs the US commercial marketing architecture inside the structure those specialists have already put in place. When a marketing decision carries regulatory, clinical, reimbursement, or legal implications, the firm flags it and defers before execution.
Three stages in order. Diagnose where the US commercial frame is breaking against the FDA pathway: which US commercial layers (US KOL, US payer, US clinical-society visibility, US health-system procurement, US Medicare coding) are missing or thin, where the MDR-to-FDA translation is being treated as automatic, and which US readers are encountering home-market language that they do not complete. Correct the signal: rebuild the US commercial frame at the front with the US clinical category named in US-legible terms, the US KOL panel built at category-relevant US academic medical centres, the US value dossier drafted to AMCP and US-commercial-payer standards, the US Medicare coding-pathway groundwork started for CPT, HCPCS, APC, and ICD-10 work as relevant, and the US health-system procurement readiness staged at named US integrated delivery networks. Rebuild the execution layer in parallel with the FDA pathway: US-facing principal and clinical-team bios, US KOL relationships and advisory panels, US-facing site and sales architecture, US clinical-society and US conference plan, US payer-facing materials, and US health-system procurement-facing materials. Delivered through the Market Entry Sprint, the Cross-Border Build, or the Group Partnership depending on portfolio shape.
The full pillar on non-US medtech and biotech firms entering US health-system, US KOL, and US payer commercialisation across corridors.
Read the pillar →Munich medtech principals inside the Siemens Healthineers ecosystem and the Bavarian medical-device cluster working into US health-system procurement.
See the Munich gate →Munich operator-archetype reading: who is leaving Munich for the US, what they carry, and where the commercial frame breaks.
See Munich operators →The corridor-level pillar on German operators entering the United States across regulatory, payer, KOL, and procurement architecture.
Read the guide →The pillar on DACH Mittelstand industrials, engineering, and manufacturing operators entering US procurement.
Read the pillar →Market Entry Sprint, Cross-Border Build, Group Partnership.
See the engagements →